Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part I)

Qing Liu; Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part I)

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Part I of the article that describes confirmatory adaptive platform trial (CAPT) design for COVID-19 treatment development. In the Introduction, we provide generate description of ACTT, CATCO and SOLIDARITY trials which are emerging as confirmatory trials. We then describe key elements of CAPT design, followed by legal and regulatory requirement for confirmatory trial designs.

Original language	American English
Journal	LinkedIn
State	Published - May 10 2020

Disciplines

Biostatistics
Environmental Public Health
Epidemiology
Public Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.linkedin.com/pulse/statistical-considerations-clinical-trials-during-trial-asa-fellow/?trackingId=9EXmRojiTXmdCdC0VytyiA%3D%3D

Cite this

@article{0d972231fa974a68b1007a81f33c9282,

title = "Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part I)",

abstract = " Part I of the article that describes confirmatory adaptive platform trial (CAPT) design for COVID-19 treatment development. In the Introduction, we provide generate description of ACTT, CATCO and SOLIDARITY trials which are emerging as confirmatory trials. We then describe key elements of CAPT design, followed by legal and regulatory requirement for confirmatory trial designs.",

author = "Qing Liu and Peace, {Karl E.}",

year = "2020",

month = may,

day = "10",

language = "American English",

journal = "LinkedIn",

}

TY - JOUR

T1 - Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part I)

AU - Liu, Qing

AU - Peace, Karl E.

PY - 2020/5/10

Y1 - 2020/5/10

N2 - Part I of the article that describes confirmatory adaptive platform trial (CAPT) design for COVID-19 treatment development. In the Introduction, we provide generate description of ACTT, CATCO and SOLIDARITY trials which are emerging as confirmatory trials. We then describe key elements of CAPT design, followed by legal and regulatory requirement for confirmatory trial designs.

AB - Part I of the article that describes confirmatory adaptive platform trial (CAPT) design for COVID-19 treatment development. In the Introduction, we provide generate description of ACTT, CATCO and SOLIDARITY trials which are emerging as confirmatory trials. We then describe key elements of CAPT design, followed by legal and regulatory requirement for confirmatory trial designs.

UR - https://digitalcommons.georgiasouthern.edu/bee-facpubs/163

UR - https://www.linkedin.com/pulse/statistical-considerations-clinical-trials-during-trial-asa-fellow/?trackingId=9EXmRojiTXmdCdC0VytyiA%3D%3D

M3 - Article

JO - LinkedIn

JF - LinkedIn

ER -

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part I)

Abstract

Disciplines

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this